Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Pediatric Endocrinology

How Is the Initial Sex of Rearing Chosen in 46,XY DSD?

At a Glance

In 46,XY DSD, the initial sex of rearing is an individualized decision made with a specialized team after urgent health risks and the specific diagnosis are assessed. Puberty, hormones, fertility, gonadal tumor risk, and delaying nonurgent surgery are considered, but no test can predict future gender identity.

When a newborn is diagnosed with a 46,XY difference of sex development (DSD), the medical team does not rely solely on chromosomes or genital appearance to recommend raising the child as a boy or a girl. Instead, choosing the initial sex of rearing (how the child is raised) is a highly individualized, multidisciplinary decision [1].

A specialized care team—including pediatric endocrinologists, geneticists, urologists, and psychologists—works closely with parents. It is important to understand that while doctors and parents choose an initial sex of rearing, they cannot assign or predict a child’s future gender identity (the person’s own internal sense of their gender) [2]. A later change in gender identity is not a medical complication or a failure, but rather a reflection of the child’s natural development [3].

Medical Safety First

Before deciding on sex of rearing, the immediate priority is ensuring the baby is physically healthy. The team will run tests to rule out life-threatening conditions, such as salt-wasting disorders or adrenal insufficiency, which require urgent medical treatment [1]. Once the baby’s immediate health is stable, the team will work with you to understand the specific diagnosis.

The Role of the Specific Diagnosis

Identifying the exact genetic and biochemical cause of the DSD is a critical step [4]. Different genetic variations affect how the body produces and responds to androgens (hormones, like testosterone, that drive male physical traits).

For example, conditions like 5-alpha reductase type 2 deficiency (5ARD) and 17-beta hydroxysteroid dehydrogenase type 3 deficiency (17BHSD3) involve specific enzyme differences that affect testosterone processing [5]. While some older studies note that some individuals with these diagnoses who were raised female later identified as male, these statistics come from small, historical groups of patients across different cultures [6][7]. A genetic diagnosis provides important clues about how the child’s body might develop, but it cannot reliably predict an individual child’s future gender identity [8].

Key Factors Weighed by the Care Team

When discussing the initial plan for sex of rearing, the team evaluates several overlapping factors:

  • Expected Puberty and Hormone Needs: The team projects what changes the child’s body will naturally undergo [9]. For instance, children with 5ARD or 17BHSD3 often experience spontaneous virilization (masculinization, such as voice deepening and muscle growth) at puberty [10]. Understanding this helps parents anticipate future needs. Depending on whether internal reproductive organs are retained or removed, and how they function, the child may need hormone replacement therapy (testosterone or estrogen) for bone and general health regardless of the chosen sex of rearing [9].
  • Prenatal Androgen Exposure: The medical team may discuss the estimated degree to which the baby’s brain and body were exposed to androgens in the womb. While historical research sometimes attempts to link this exposure to later behavior or identity, this exposure is usually inferred rather than directly measured, and evidence is mixed [2]. The care team considers it, but prenatal hormone exposure is not a dependable test and cannot reliably predict an individual child’s future gender identity [3].
  • Fertility Potential: Preserving the potential to have biological children is a consideration, though fertility is often limited in 46,XY DSD [11]. Depending on the diagnosis, retaining testicles might allow for future fertility using assisted reproduction, though sperm production is frequently impaired [9]. Fertility potential is a separate medical issue from sex of rearing.
  • Gonadal Management and Tumor Risk: Streak gonads (incompletely developed reproductive organs) that contain Y-chromosome material can sometimes carry a higher risk of developing germ-cell tumors (a type of abnormal cellular growth) [12]. Gonadal management—whether to remove, closely monitor, or surgically reposition the gonads—is based on cancer risk, hormone function, and future fertility [13][14]. Removing gonads creates a lifelong need for hormone replacement therapy.

Predicting a child’s future gender identity is incredibly difficult [15]. Because of this uncertainty, modern medical guidance supports deferring non-urgent, non-medically necessary genital surgeries [15][13].

Some surgical interventions may be medically necessary right away—for example, to treat urinary blockages, prevent recurrent infections, or manage pain [13]. However, delaying surgeries that are solely for cosmetic appearance leaves options open. This approach preserves the child’s bodily autonomy, allowing them to participate in shared decision-making regarding their own body and identity as they grow older [15].

Glossary of Terms

  • 46,XY DSD: A broad medical term for conditions where a person has typical male chromosomes (XY) but their reproductive organs or genital development differ from typical male development.
  • Androgens: Hormones, like testosterone, that drive male physical traits.
  • Sex of Rearing: The social sex (boy or girl) a child is raised and presented as.
  • Gender Identity: A person’s deeply felt, internal sense of being male, female, or another gender.
  • Virilization: The physical development of male characteristics, such as body hair or a deeper voice.
  • Streak Gonads: Incompletely formed reproductive tissue that usually does not produce typical hormones or fertility cells.

Common questions in this guide

What factors determine whether a baby with 46,XY DSD is raised as a boy or a girl?
The decision is individualized by the parents and a multidisciplinary care team after urgent health problems are evaluated and the specific diagnosis is understood. The team considers expected puberty, hormone needs, fertility potential, gonadal tumor risk, anatomy, and the child's future options.
Can genetic testing predict my child's future gender identity?
No. Genetic and hormone-related findings can provide clues about physical development, but they cannot reliably predict an individual child's gender identity, which is the person's own internal sense of gender.
Why might genital surgery be postponed in 46,XY DSD?
Nonurgent surgery done only for appearance may be delayed because future gender identity is difficult to predict and the child may later want to participate in decisions about their body. Surgery may still be needed sooner to treat problems such as urinary blockage, recurrent infections, or pain.
What could happen at puberty with 46,XY DSD?
The pubertal course depends on the specific diagnosis and how the body produces or responds to hormones. Some children with 5-alpha reductase type 2 deficiency or 17-beta hydroxysteroid dehydrogenase type 3 deficiency may develop more male physical traits at puberty, such as a deeper voice and increased muscle growth, and hormone replacement may be needed for bone and general health.
Does removing or keeping the gonads affect future care?
Yes. The team weighs tumor risk, hormone production, and possible fertility when deciding whether to remove, monitor, or reposition the gonads. Removing gonads leads to a lifelong need for hormone replacement, while keeping them may require ongoing monitoring and does not guarantee fertility.
Can a child with 46,XY DSD have biological children?
Fertility varies by diagnosis and is often limited because sperm production may be impaired. In some cases, keeping the testicles may preserve the possibility of future fertility with assisted reproduction, so families can ask about long-term fertility planning and preservation options.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is our child's specific genetic and biochemical diagnosis, and are there any urgent health issues we need to monitor right now?
  2. 2.Which surgical procedures are medically necessary for our baby’s physical health, and which can safely be delayed until our child is older?
  3. 3.Based on the diagnosis, what is the expected pubertal course, and what might our child's future hormone replacement needs look like?
  4. 4.What is the specific tumor risk for our child's gonads, and what are the trade-offs between monitoring them versus removing them?
  5. 5.What is our child's realistic fertility potential, and what fertility preservation options might exist in the future?
  6. 6.How can we access specialized psychological support or peer groups for families navigating 46,XY DSD?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Diagnostic approach in 46, XY DSD: an endocrine society of bengal (ESB) consensus statement.

    Baidya A, Basu AK, Bhattacharjee R, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2023; (36(1)):4-18 doi:10.1515/jpem-2022-0515.

    PMID: 36424806
  2. 2

    Psychosexual Aspects, Effects of Prenatal Androgen Exposure, and Gender Change in 46,XY Disorders of Sex Development.

    Loch Batista R, Inácio M, Prado Arnhold IJ, et al.

    The Journal of clinical endocrinology and metabolism 2019; (104(4)):1160-1170 doi:10.1210/jc.2018-01866.

    PMID: 30388241
  3. 3

    Recalled and current gender role behavior, gender identity and sexual orientation in adults with Disorders/Differences of Sex Development.

    Callens N, Van Kuyk M, van Kuppenveld JH, et al.

    Hormones and behavior 2016; (86()):8-20 doi:10.1016/j.yhbeh.2016.08.008.

    PMID: 27576114
  4. 4

    Genetic and Clinical Characteristics of 185 Japanese Children With 46,XY Differences of Sex Development.

    Hayashi M, Narumi S, Sato T, et al.

    The Journal of clinical endocrinology and metabolism 2025; (110(8)):e2682-e2690 doi:10.1210/clinem/dgae813.

    PMID: 39569443
  5. 5

    Screening for mutations in 17β-hydroxysteroid dehydrogenase and androgen receptor in women presenting with partially virilised 46,XY disorders of sex development.

    Phelan N, Williams EL, Cardamone S, et al.

    European journal of endocrinology 2015; (172(6)):745-51 doi:10.1530/EJE-14-0994.

    PMID: 25740850
  6. 6

    Integrative and Analytical Review of the 5-Alpha-Reductase Type 2 Deficiency Worldwide.

    Batista RL, Mendonca BB

    The application of clinical genetics 2020; (13()):83-96 doi:10.2147/TACG.S198178.

    PMID: 32346305
  7. 7

    Gonadal function and pathology in 17beta-HSD 3 and 5alpha-reductase deficiency.

    Boogers LS, Brüggenwirth HT, Wolffenbuttel KP, et al.

    European journal of endocrinology 2025; (192(1)):34-45 doi:10.1093/ejendo/lvae154.

    PMID: 39782875
  8. 8

    5-α-Reductase type 2 deficiency: is there a genotype-phenotype correlation? A review.

    Avendaño A, Paradisi I, Cammarata-Scalisi F, Callea M

    Hormones (Athens, Greece) 2018; (17(2)):197-204 doi:10.1007/s42000-018-0013-9.

    PMID: 29858846
  9. 9

    Guidance for shared decision-making regarding orchiectomy in individuals with differences of sex development due to 17-β-hydroxysteroid dehydrogenase type 3 deficiency.

    Yu LX, Johnson J, Pennesi CM, et al.

    Frontiers in pediatrics 2025; (13()):1549400 doi:10.3389/fped.2025.1549400.

    PMID: 40051913
  10. 10

    Steroid 5α-reductase 2 deficiency.

    Mendonca BB, Batista RL, Domenice S, et al.

    The Journal of steroid biochemistry and molecular biology 2016; (163()):206-11.

    PMID: 27224879
  11. 11

    Testicular cytology and semen analysis in 46, XY differences/disorders of sex development (DSD): implications for fertility.

    Gazula S, Sharma S, Iyer VK, Gupta DK

    Pediatric surgery international 2025; (42(1)):38 doi:10.1007/s00383-025-06276-4.

    PMID: 41396231
  12. 12

    Clinical Spectrum, Surgical Management, and Outcomes of NR5A1-Related 46,XY Differences of Sex Development: A Narrative Review.

    Vicario S, Escolino M, Esposito G, et al.

    Medicina (Kaunas, Lithuania) 2025; (61(11)) doi:10.3390/medicina61111965.

    PMID: 41303802
  13. 13

    Surgery in disorders of sex development (DSD) with a gender issue: If (why), when, and how?

    Mouriquand PD, Gorduza DB, Gay CL, et al.

    Journal of pediatric urology 2016; (12(3)):139-49.

    PMID: 27132944
  14. 14

    Gonadal dysgenesis in disorders of sex development: Diagnosis and surgical management.

    Wolffenbuttel KP, Hersmus R, Stoop H, et al.

    Journal of pediatric urology 2016; (12(6)):411-416 doi:10.1016/j.jpurol.2016.08.015.

    PMID: 27769830
  15. 15

    Spectrum and genotype-phenotype correlation of NR5A1 variants in 46,XY DSD: a systematic review and meta-analysis.

    Dallago RT, Batista RL, Domenice S, et al.

    Endocrine connections 2026; (15(5)).

    PMID: 41989314

This page explains how sex-of-rearing decisions may be approached in 46,XY DSD for informational purposes only and does not constitute medical advice. Your child's specialized care team can interpret the diagnosis and discuss choices for your family.

Get notified when new evidence is published on 46,XY difference of sex development.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.